异基因造血干细胞移植治疗慢性粒-单核细胞白血病的临床分析  

Clinical Analysis on Treatment of Chronic Myelomonocytic Leukemia with Allogeneic Hematopoietic Stem Cell Transplantation

作　　者：王彤[1] 李渭阳[1] 祁小飞[1] 张日[1] 金正明[1] 仇惠英[1] 韩悦[1] 马骁[1] 付琤琤[1] 唐晓文[1] 陈苏宁[1] 孙爱宁[1] 吴德沛[1] 

机构地区：[1]苏州大学附属第一医院,江苏省血液研究所,卫生部血栓与止血重点实验室,血液学协同创新中心,江苏苏州215006

出　　处：《中国实验血液学杂志》2015年第6期1667-1672,共6页Journal of Experimental Hematology

基　　金：江苏省科教兴卫工程-临床医学中心(ZX201102);国家临床重点专科建设项目

摘　　要：目的:回顾性分析异基因造血干细胞移植(allo-HSCT)治疗慢性粒-单核细胞白血病(CMML)的疗效。方法:通过观察13例CMML患者在接受allo-HSCT后造血植入、移植物抗宿主病(GVHD)、感染、复发及生存情况,分析allo-HSCT治疗CMML的临床疗效。结果:13例患者中,男性10例,女性3例;中位年龄38(21-50)岁,其中非亲缘相合移植4例,同胞相合移植6例,亲缘单倍体相合移植3例。13例患者全部获得供者型植入,粒系植入中位时间12(11-18)d,巨核系植入中位时间15(10-55)d,其中8例患者发生急性GVHD,中位随访时间13(6-29)个月,总体生存率53.8%,无病生存率53.8%,复发率7.7%。结论:Allo-HSCT可以改善CMML患者的生存,是治疗CMML的有效手段。Objective:To analyze retrospectively the therapeutic efficacy of allogeneic hematopoietic stem cell transplantation(allo-HSCT) for chronic myelomonocytic leukemia(CMML).Methods:The engraftment,graft versus host disease(GVHD),infection,relapse,and survival of 13 CMML patients received allo-HSCT were observed.The clinical outcome of allo-HSCT for CMML was analyzed.Results:Thirteen(10 males and 3 females) CMML patients with a median age of 38 years old received allo-HSCT including 4 from HLA-matched unrelated donors,6 from HLAmatched sibling donors and 3 from haploidentical related donors.All 13 patients achieved engraftment,and the median time of neutrophil engraftment and platelet engraftment were 12(11-18) days and 15(10-55) days respectively,acute GVHD occurred in 8 patients.After the median follow-up of 13(6-29) months,the overall survival,disease free survival and relapse were 53.8%,53.8%,7.7%,respectively.Conclusion:Allo-HSCT can improve the survival of patients with CMML,and is a effective method for treatment of CMML.

关 键 词：白血病 粒-单核细胞 造血干细胞移植 

分 类 号：R733.72[医药卫生—肿瘤]